FDA Inspection
KBI Biopharma, Inc.KBI Biopharma, Inc. – FDA Inspection, Jun 18, 2024
Record Details
This FDA Inspection record concerns KBI Biopharma, Inc., with an inspection on June 18, 2024, issued by the Atlanta District Office, covering human drugs.
- Office
- Atlanta District Office
- People
- Ayyappan Rathakrishnan (Issuing Officer)
- Kamal N. Tiwari (Issuing Officer)
- Olumide A. Martins (Issuing Officer)
View Company Profile
ID · 5cd2e622-d49c-44b5-b6e3-44ca23f7bcc6
Inspection Facts
- Inspection number
- 1241524
- FDA center
- Human Drugs
- Outcome
- Form 483 issued
Other FDA inspections of KBI Biopharma, Inc.
5| Date | Classification | Office | Project area |
|---|---|---|---|
| April 1, 2026 | Not classified | Atlanta District Office | |
| April 11, 2018 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| July 16, 2015 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| August 29, 2012 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| October 9, 2009 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for KBI Biopharma, Inc.
- FDA Inspection 1312108 - 2026-04-01
- FDA Inspection 1051652 - 2018-04-11
- FDA Inspection 937768 - 2015-07-16
- FDA Inspection 796226 - 2012-08-29
- FDA Inspection 625271 - 2009-10-09
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.